Drug Trial Radar · NCT07185815
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Dec 31, 2026
Study completion Jun 3, 2027
Sponsor
- Lead sponsor
- Mapi Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine Depot in subjects eligible for treatment with oral Cariprazine.
Conditions
- Schizophrenia
- Bipolar I Disorder
- Major Depressive Disorder
Interventions
Cariprazine DepotDrug
One single dose of 22 mg
Cariprazine DepotDrug
One single dose of 44 mg
Cariprazine Depot MTDDrug
Three monthly doses of MTD (maximum tolerated dose)
Oral Cariprazine 3 mg/dayDrug
Oral Cariprazine 3 mg/day for three months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety, rate of adverse events (AEs)Time frame: Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort
- Plasma concentration of cariprazine and its active metabolites (DCAR, DDCAR)Time frame: Through study completion, up to 22 weeks for each subject in the first 2 cohorts and up to 24 weeks for each subject in the 3rd cohort
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Mapi Pharma Investigational Site IN-101
Ahmedabad, India · Recruiting
Mapi Pharma Investigational Site IN-102
Ahmedabad, India · Recruiting
Mapi Pharma Investigational Site IL-004
Beersheba, Israel · Recruiting
Mapi Pharma Investigational Site IL-003
Ness Ziona, Israel · Recruiting
Mapi Pharma Investigational Site IL-005
Ramat Gan, Israel · Recruiting
Mapi Pharma Investigational Site IL-001
Tel Aviv, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.